Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Get the full story at our sister site, Drug Delivery Business News.
Pain Management
NeuroMetrix stock slides on publication of Quell study
NeuroMetrix (NSDQ:NURO) stock is hitting a massive skid this week after the publication of a study on its Quell non-invasive nerve stimulation device for pain relief. Shares of NURO were down -12.2% at $18.41 apiece by late-afternoon trading yesterday on the news. The stock continues to decline today, down –7.1% to $16.94 per share by […]
Johnson & Johnson, other companies to pay $26B over opioid crisis
California Attorney General Rob Bonta announced a $26 billion settlement with Johnson & Johnson, among other companies, over opioids. The settlement includes Johnson & Johnson, which manufactured and marketed opioids, and pharmaceutical distributors Cardinal, McKesson and AmerisourceBergen. Get the full story at our sister site, Pharmaceutical Processing World.
NeuroMetrix’s Q2 earnings report sends its stock to new heights
NeuroMetrix (NSDQ:NURO) shares saw a huge boost this today on strong second-quarter revenues and an increased bottom line. NURO shares were up 19.1% at $24.77 per share in mid-afternoon trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.4%. The Woburn, Mass.-based company posted losses […]
The 18 most innovative medical devices of 2021
The Galien Foundation today announced the nominees for most innovative medical devices for its 15th annual Prix Galien USA Awards. The foundation nominates devices, biotechnology and pharmaceutical products for its annual Prix Galien awards to highlight products designed to improve the human condition. “The Awards Committee is excited to introduce the nominees for the 2021 […]
NeuroMetrix stock skyrockets on news of FDA breakthrough device designation
NeuroMetrix (NSDQ:NURO) today announced that its Quell device has received FDA breakthrough designation for treating fibromyalgia symptoms in adults. The news saw NURO shares nearly triple in value to $9.72 apiece near the close of trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up 1.5%. Fibromyalgia involves the […]
FDA approves Nevro’s Senza system to treat chronic pain with diabetic neuropathy
Nevro (NYSE:NVRO) announced today that it received FDA approval for its Senza system for treating chronic pain associated with PDN. The Redwood City, Calif.-based company’s stock was up nearly 6%, to 152.54 per share, by afternoon trading today. Nevro’s Senza system’s approval is specific to Nevro’s 10 kHz stimulation. The company is touting that it […]
Fresenius Kabi launches Simplist fentanyl citrate injection
Fresenius Kabi announced today that it initiated the U.S. introduction of a fentanyl citrate injection in the Simplist pre-filled syringe. Lake Zurich, Ill.-based Fresenius Kabi’s proprietary Simplist ready-to-administer prefilled syringe offers the fentanyl citrate injection at 50 mcg per 1 mL in an effort to reduce waste and diversion while ensuring the safe delivery of medication. […]
Mainstay Medical launches implantable neurostim system in U.S.
Mainstay Medical today announced the limited commercial launch of its ReActiv8 implantable restorative neurostimulation system in the U.S. The Ireland-based company designed ReActiv8 to treat intractable chronic lower back pain. The system will be available in the U.S. through ReActiv8-certified physicians this summer. “Supported by more than 10 years of clinical research, ReActiv8 is the […]
NeuroMetrix reports mixed results in fibromyalgia trial
NeuroMetrix (NSDQ:NURO) announced a mixed bag of top-line results from its trial of Quell in patients with fibromyalgia. Woburn, Mass.–based NeuroMetrix’s double-blind, randomized, sham-controlled trial evaluated the treatment of fibromyalgia with Quell, an over-the-counter novel transcutaneous electrical nerve stimulator (TENS) indicated for symptomatic relief and management of chronic lower extremity pain. Quell, a wearable device […]
NeuroOne gains Nasdaq listing
NeuroOne Medical Technologies (OTC:NMTC) announced that it was approved to uplist and begin trading on the Nasdaq market. Eden Prairie, Minn.-based NeuroOne expects trading to commence today at the open of the market, with the company trading under the “NMTC” ticker, according to a news release. The developer of surgical care options for patients suffering […]
